Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease

Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paedi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouldthorpe, Oliver, Catto-Smith, Anthony G., Alex, George, Simpson, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817600/
https://www.ncbi.nlm.nih.gov/pubmed/24275852
http://dx.doi.org/10.3390/ph6101322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817600/
https://www.ncbi.nlm.nih.gov/pubmed/24275852
http://dx.doi.org/10.3390/ph6101322

Ejemplares similares